Hepatitis C

1,000 patients enrolled in phase III hepatitis C trials evaluating Zadaxin

Published in Hepatitis Weekly, June 14th, 2004

SciClone Pharmaceuticals, Inc., (SCLN) announced that a total of 1,000 patients have been enrolled in its two U.S. phase III hepatitis C (HCV) clinical trials evaluating its lead product, Zadaxin.

SciClone has earned a $1,000,000 milestone payment from Sigma-Tau for successfully meeting the enrollment objective. SciClone expects all patients to have completed therapy and the observation period by the end of 2005. Data from both trials are expected to be available in early 2006.

Eduardo Martins, vice president of Medical Affairs of SciClone, commented, "We are pleased to reach this milestone in our efforts to develop the combination of Zadaxin and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-06-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry